The impact of anti-thymocyte globulin on the outcomes of patients with aml with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation - Université de Lille Accéder directement au contenu
Article Dans Une Revue Leukemia Année : 2020

The impact of anti-thymocyte globulin on the outcomes of patients with aml with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation

Résumé

Measurable residual disease (MRD) status pre-allogeneic hematopoietic cell transplantation (allo-HCT) has been shown to predict transplant outcomes. We investigated the effect of Anti-Thymocyte Globulin (ATG) on acute myelogenous leukemia (AML) relapse by pretransplant MRD status. AML patients undergoing allo-HCT in first complete remission from either a matched sibling or unrelated donor during the 2006-2017 period were selected. Outcomes of 1509 patients (MRD+-+-++
Fichier non déposé

Dates et versions

hal-04426592 , version 1 (30-01-2024)

Identifiants

Citer

Arnon Nagler, Bhagirathbhai Dholaria, Myriam Labopin, Gerard Socie, Anne Huynh, et al.. The impact of anti-thymocyte globulin on the outcomes of patients with aml with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. Leukemia, 2020, Leukemia, 34, pp.1144-1153. ⟨10.1038/s41375-019-0631-5⟩. ⟨hal-04426592⟩
8 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More